OTC:JRSS
JRSIS HEALTH CARE Corp
A high-growth healthcare innovator balancing heavy R&D expenditures with improving operational cash flows and revenue expansion.
Key Metrics
Investment Thesis
Bull Case
JRSS offers a compelling turnaround story with revenue exploding from $0.1M to $3.5M in a single year, indicating massive market potential. The company generates strong positive operating cash flow ($516k) which can fund its R&D initiatives without immediate equity dilution. Early-stage biotech or healthcare firms often trade at low valuations that provide significant upside if their proprietary products gain regulatory approval or commercial traction.
Bear Case
Investors should avoid this stock due to the massive negative shareholders' equity of $-160k and a retained earnings deficit of $-3.4M, which signal potential insolvency risks. The company's profitability is heavily distorted by non-cash adjustments of $-404k and high interest expenses relative to cash on hand. With only one year of meaningful revenue data and persistent net losses, the path to sustainable profitability remains unproven.
About JRSIS HEALTH CARE Corp
JRSIS HEALTH CARE Corp (JRSS) operates within the healthcare sector, leveraging significant investments in research and development to drive innovation. The company has recently scaled its revenue operations, generating $3.5M in 2023 compared to minimal prior activity. Despite a net loss narrowing from $-33.7M to $-94k, the firm maintains substantial operating cash flow of $516k.
Analysis
Management Discussion
Management successfully navigated the transition from negligible revenue in 2022 to $3.5M in 2023, demonstrating strong execution in market penetration. While net profit remains negative at $-94k, positive operating cash flow of $516k suggests the business model is generating liquidity despite accounting charges. The narrowing loss from $-33.7M to $-0.1M reflects operational maturity and scaling efficiencies.
Industry Overview
The healthcare industry is characterized by high regulatory barriers, intense R&D competition, and long development cycles for new treatments or devices. Companies in this sector often experience significant volatility in earnings due to patent cliffs, clinical trial outcomes, and reimbursement policy changes. JRSS operates in a niche where innovation drives value but capital efficiency is critical for survival.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 |
|---|---|---|
| Revenue | $89.2K | $3.5M |
| Cost of Revenue | $0 | $3.0M |
| Gross Profit | $89.2K | $483.1K |
| Operating Expenses | $415.1K | $671.6K |
| Operating Income | $-325.9K | $-188.6K |
| R&D | — | $189.3K |
| G&A | — | $336.0K |
| Marketing | — | $146.3K |
| Stock-Based Comp | $245.5K | — |
| D&A | $5.8K | $53.8K |
| Depreciation | $5.8K | $16.5K |
| Amortization | — | $37.3K |
| Other OpEx | — | $0 |
| Non-Operating Income | $-1.7K | $103.0K |
| Interest Expense | — | $56.4K |
| Interest Income | — | $3.1K |
| Pre-Tax Income | $-327.6K | $-85.6K |
| Income Tax | $0 | $9.0K |
| Continuing Ops | $-327.6K | $-94.6K |
| Discontinued Ops | $-33.4M | $0 |
| Net Income | $-33.7M | $-94.6K |
| Minority Interest | $-35.0M | $-13.7K |
| Net to Common | $1.3M | $-80.9K |
| Metric | 2022 | 2023 |
|---|---|---|
| Current Assets | $798.9K | $1.8M |
| Cash & Equivalents | $58.6K | — |
| Accounts Receivable | — | $714.7K |
| Inventory | — | $455.2K |
| Prepaid Expenses | — | $77.2K |
| Other Current Assets | $740.2K | $586.8K |
| Long-Term Assets | $57.1K | $310.6K |
| PP&E (Net) | $39.0K | $50.0K |
| Intangibles | — | $257.3K |
| Operating Leases | — | $3.3K |
| Other LT Assets | $18.1K | $0 |
| Total Assets | $856.0K | $2.1M |
| Current Liabilities | $43.2K | $2.3M |
| Accounts Payable | $24.7K | — |
| Current Debt | — | $18.7K |
| Current Leases | — | $3.3K |
| Taxes Payable | — | $969 |
| Other Current Liab | $18.5K | $2.1M |
| Long-Term Liabilities | $1.4K | $24.9K |
| Long-Term Debt | — | $24.9K |
| Other LT Liab | — | $0 |
| Total Liabilities | $44.7K | $2.3M |
| Shareholders' Equity | $811.3K | $-160.7K |
| Paid-In Capital | $24.5M | $3.2M |
| Retained Earnings | $-23.7M | $-3.4M |
| AOCI | $6.2K | $142.9K |
| Total L&E | $856.0K | $2.1M |
| Metric | 2022 | 2023 |
|---|---|---|
| Net Income (CFO) | $-33.7M | $-94.6K |
| Non-Cash Adjustments | $36.8M | $-404.4K |
| Working Capital Changes | $-35.6K | $1.0M |
| Cash from Operations | $3.1M | $516.7K |
| Capital Expenditures | $44.6K | $1.5K |
| Cash from Investing | $-2.8M | $18.9K |
| Cash from Financing | $-738.2K | $-568.4K |
| FX Effect | $-298.1K | $-7.9K |
| Net Change in Cash | $-797.4K | $-40.7K |
| Beginning Cash | $856.0K | $158.8K |
| Ending Cash | $58.6K | $118.1K |
Frequently Asked Questions
How does JRSIS HEALTH CARE Corp make money?
The company's financial profile suggests a focus on innovative medical solutions or biotechnology, evidenced by $189k in research and development expenses and significant non-cash adjustments typical of asset-heavy or intangible-asset driven healthcare ventures. Revenue growth is concentrated in core product sales or service contracts, with gross profit margins reflecting the cost structure of specialized healthcare delivery.
What are the main risks for JRSS?
The company carries a substantial retained earnings deficit of $-3.4M and negative shareholders' equity of $-160k, indicating high financial leverage and solvency concerns. Heavy reliance on non-cash adjustments ($-404k) suggests significant depreciation or amortization impacts that distort reported profitability relative to cash reality. Interest expense of $56k against limited cash reserves creates refinancing risk in a rising rate environment.
What is JRSS's competitive advantage?
The firm has aggressively invested in R&D ($189k) to build a proprietary pipeline of healthcare solutions, potentially creating high barriers to entry. Strong operating cash flow generation ($516k) indicates efficient day-to-day management and customer demand despite accounting losses. The company successfully converted minimal prior revenue into a significant $3.5M base in 2023, signaling rapid market adoption or successful product launch cycles.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.